DBV Technologies Profile

USD 0.36  1.82%

DBV Technologies Summary

DBV Technologies S A (DBVT) is traded on BATS Exchange in USA. It is located in FRANCE and employs 244 people. DBV Technologies is listed under Pharmaceutical Products category by Fama And French industry classification.The company currently falls under 'Mid-Cap' category with current market capitalization of 1.17 B. DBV Technologies S A conducts business under Healthcare sector and is part of Pharmaceutical Products industry. This company has 24.7 M outstanding shares of which 1.12 M shares are currently shorted by private and institutional investors with about 12.89 trading days to cover. DBV Technologies S.A. currently holds about 160.63 M in cash with (133.17 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.49.
Check DBV Technologies Probability Of Bankruptcy

Ownership Allocation (%)

Target Price Odds Analysis

Odds Below 19.45HorizonTargetOdds Above 19.45
25.98%30 days 19.45 73.73%
Based on normal probability distribution, the odds of DBV Technologies to move above current price in 30 days from now is about 73.73% (This DBV Technologies S A probability density function shows the probability of DBV Technologies Stock to fall within a particular range of prices over 30 days) .

Top Holders

Selected DBV Technologies S A Income Statement Over Time

Consolidated Income    Earning Before Interest and Taxes EBIT    Net Income    

Key Fundamentals

DBV Technologies Against Markets

Current Ratings

DBV Technologies 30 Days Performance Scores
Risk Adjusted
Performance Score (0 to 100)
Chance of
Financial Distress (0 to 100%)
Equity ratings for DBV Technologies S A are calculated dynamically based on Macroaxis scoring framework. Click here to learn more
DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. DBV Technologies S.A. was founded in 2002 and is headquartered in Montrouge, France. DBV Technologies operates under Biotechnology classification in USA and traded on NASDAQ. It employs 244 people. more
Fama & French Pharmaceutical Products
Pharmaceutical Products
Fama & French Classification
DBV Technologies S SEC Filings
DBV Technologies SEC Filings
Security & Exchange Commission EDGAR ReportsView All
NameDBV Technologies S A
Chairman of the Board, CEOPierreHenri BenhamouView All
Analyst Consensus
Piotroski F Score
Macroaxis Advice
Healthcare, Biotechnology
InstrumentUSA Stock View All
Business Address177-181 avenue Pierre Brossolette
ExchangeBATS Exchange
IndustryPharmaceutical Products
Phone33 1 55 42 78 78
CurrencyUSD - US Dollar

Current Sentiment - DBVT

DBV Technologies S Investor Sentiment
Most of Macroaxis users are currently bullish on DBV Technologies S A. What is your opinion about investing in DBV Technologies S A? Are you bullish or bearish?
98% Bullish
2% Bearish

DBV Technologies Corporate Directors

Rafaele Tordjman Director - Representative of Sofinnova Partners
Pascale Ehouarn Industrial Development and Production Director
Claude Thebault Medical Director
Additionally see Investing Opportunities. Please also try World Markets Correlation module to find global opportunities by holding instruments from different markets.